Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Feb 21, 2025, 4:00 PM
2.000
-0.050 (-2.44%)
After-hours: Feb 21, 2025, 7:54 PM EST
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 4.40, with a low estimate of 3.00 and a high estimate of 7.50. The average target predicts an increase of 114.63% from the current stock price of 2.05.
Analyst Consensus: Buy
* Price targets were last updated on Nov 19, 2024.
Analyst Ratings
The average analyst rating for Akoya Biosciences stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +46.34% | Nov 19, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +143.90% | Nov 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $3.5 | Strong Buy | Maintains | $6 → $3.5 | +70.73% | Nov 15, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +95.12% | Aug 13, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $4 → $3 | Buy → Hold | Downgrades | $4 → $3 | +46.34% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
83.49M
from 96.63M
Decreased by -13.60%
Revenue Next Year
93.42M
from 83.49M
Increased by 11.90%
EPS This Year
-1.12
from -1.43
EPS Next Year
-0.63
from -1.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 87.2M | 98.7M | 117.6M | |||
| Avg | 83.5M | 93.4M | 107.5M | |||
| Low | 78.9M | 87.2M | 90.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -9.8% | 18.2% | 25.9% | |||
| Avg | -13.6% | 11.9% | 15.0% | |||
| Low | -18.4% | 4.5% | -2.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.96 | -0.46 | -0.36 | |||
| Avg | -1.12 | -0.63 | -0.46 | |||
| Low | -1.13 | -0.70 | -0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.